SCHEMBL3010397

SCHEMBL3010397

COc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4ccc(Cl)cc4)CC3)n2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.59
LMNA P02545 5/20 0.59
SMN1; SMN2 Q16637 4/20 0.59
POLB P06746 3/20 0.59
MAPK1 P28482 2/20 0.59
KMT2A Q03164 3/20 0.51
GAA P10253 1/20 0.51
HSD17B10 Q99714 2/20 0.49
USP2 O75604 1/20 0.49
MAPT P10636 1/20 0.49
RECQL P46063 1/20 0.49
PKM P14618 3/20 0.49
TSHR P16473 3/20 0.49
NPC1 O15118 1/20 0.49
PKLR P30613 1/20 0.49
RAB9A P51151 1/20 0.49
MEN1 O00255 1/20 0.47
HTT P42858 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
ALOX12 P18054 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3004528 0.95 PKM (0.54) ALDH1A1LMNASMN1; SMN2POLBMAPK1
SCHEMBL3007797 0.92 SMN1; SMN2 (0.51) ALDH1A1LMNASMN1; SMN2POLBMAPK1
SCHEMBL3003684 0.91 LMNA (0.47) ALDH1A1LMNASMN1; SMN2POLBMAPK1
SCHEMBL3004407 0.91 MAPT (0.51) ALDH1A1LMNASMN1; SMN2POLBMAPK1
SCHEMBL3013112 0.91 KMT2A (0.52) ALDH1A1LMNASMN1; SMN2POLBMAPK1
SCHEMBL3011855 0.91 KMT2A (0.52) ALDH1A1LMNASMN1; SMN2POLBMAPK1
SCHEMBL3016522 0.90 POLB (0.48) ALDH1A1LMNASMN1; SMN2POLBMAPK1
SCHEMBL3009005 0.90 TDP1 (0.60) ALDH1A1LMNASMN1; SMN2POLBMAPK1
SCHEMBL3016487 0.90 MAPT (0.49) ALDH1A1LMNASMN1; SMN2POLBMAPK1
SCHEMBL3007698 0.90 MAPT (0.61) ALDH1A1LMNASMN1; SMN2POLBMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885LMNA 80/4885SMN1; SMN2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.